Section snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Section snippets Funding Support and Author DisclosuresDr Karam has received consultant fees from Edwards Lifesciences, Boston Scientific, and Medtronic; and has received proctor fees from Abbott. Dr Stolz received speaker honoraria from Edwards Lifesciences. Dr Lurz has received institutional fees and research grants from Abbott Cardiovascular, Edwards Lifesciences, and ReCor; has received honoraria

No Abstract

BackgroundCurrent guidelines recommend a strategy of clinical surveillance (CS) for patients with asymptomatic severe aortic stenosis (AS) and normal left ventricular ejection fraction. ObjectivesTo conduct a study-level meta-analysis of randomized controlled trials (RCTs) evaluating the effect of early aortic valve replacement (AVR) compared with CS in patients with asymptomatic severe AS. MethodsStudies

No Abstract

BackgroundMineralocorticoid receptor antagonists (MRA) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF) but are underused in clinical practice. Observational data suggest that hyperkalemia is the leading obstacle for the suboptimal use of MRA. ObjectivesWe evaluated the effects of sodium zirconium cyclosilicate (SZC) in optimizing use of spironolactone among participants

BACKGROUNDTransthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a fatal disease, caused by misfolded transthyretin depositing as amyloid fibrils in the heart. Because disease progression is common, practical and sensitive methods are needed to monitor patients and optimize treatment decisions. Outpatient worsening heart failure (HF) (oral loop diuretic intensification or initiation) is simple

No Abstract

Section snippets Associations of Self-Reported Race, Social Determinants of Health, and Polygenic Risk With Coronary Heart Disease 2157Kristjan Norland, Daniel J. Schaid, Mohammadreza Naderian, Jie Na, Iftikhar J. KulloIn a study of 67,256 All of Us participants, the authors tested the associations of self-reported race/ethnicity, social determinants of health (SDOH), and polygenic risk with coronary

BackgroundSocial determinants of health (SDOH) influence the risk of common diseases such as coronary heart disease (CHD). ObjectivesThis study sought to test the associations of self-reported race/ethnicity, SDOH, and a polygenic risk score (PRS), with CHD in a large and diverse U.S. cohort. MethodsIn 67,256 All of Us (AoU) participants with available SDOH and whole-genome sequencing data, we ascertained

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

BackgroundHypertension is common in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), and current guidelines recommend treating systolic blood pressure (SBP) to a target below 130 mmHg. However, data supporting treatment to this target is limited. Additionally, pulse pressure (PP), a marker of aortic stiffness, has been associated with increased risk of

Section snippets Funding Support and Author DisclosuresThe author has reported that he has no relationships relevant to the content of this paper to disclose.

No Abstract

Section snippets Funding Support and Author DisclosuresDr Stroes has received lecturing/Advisory Board fees from Amgen, Sanofi, Novo Nordisk, Novartis, Ionis, and AstraZeneca. The other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

BackgroundNT-proBNP and hs-cTnT are associated with cardiovascular outcomes and are recommended for measurement in type 2 diabetes (T2D). However, the effects of an intensive lifestyle intervention (ILI) targeting weight loss on cardiac biomarkers and the prognostic association of changes in these biomarkers with risk of adverse cardiovascular outcomes in T2D are not well-established. ObjectivesTo

Section snippets Funding Support and Author DisclosuresDr Kim has received research funding from the National Institutes of Health (T32HL160522). Dr Yeh has received research funding from Boston Scientific, Abbott, and Medtronic; and has served as a consultant for Boston Scientific, Abbott, Medtronic, Edwards Lifesciences, CathWorks, and Shockwave. Dr Secemsky has received research funding from the

Section snippets Funding Support and Author DisclosuresDr Marinacci has received research support from grant T32-HL160522 from the National Institutes of Health. Dr Wadhera has received research support from the National Heart, Lung, and Blood Institute at the National Institutes of Health (R01HL164561, R01HL174549), the National Institute for Nursing Research at the National Institutes of Health (R01NR021686)

BackgroundWhether age impacts the recently demonstrated survival benefit of microaxial flow pump (mAFP) treatment in patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock (CS) is unknown. ObjectivesThe purpose of this study was to assess the impact of age on mortality and complication rates in patients with STEMI-related CS randomized to standard care or mAFP on top

No Abstract

Section snippets Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention 2073Renato D. Lopes, Steven J. Atlas, Alan S. Go, Steven A. Lubitz, David D. McManus, Rowena J. Dolor, Ranee Chatterjee, Michael B. Rothberg, David R. Rushlow, Lori A. Crosson, Ronald S. Aronson, Michael Patlakh, Dianne Gallup, Donna J. Mills, Emily C. O’Brien, Daniel E. SingerAlthough randomized trials using

Section snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Section snippets Serving the Cardiovascular Community: The Power of IntegrationOur goal is simple but transformative: to better serve the cardiovascular community by delivering the highest-quality content in a more integrated and efficient manner. Readers care more about the science than the specific journal in which it appears. By coordinating our efforts across JACC and JACC: Clinical Electrophysiology

Section snippets The Landscape of Cardiovascular Employment ModelsThere are roughly 6 distinct types of employment models in today’s cardiovascular practice landscape, spanning from the more traditional models of independent practice and academic medicine to newer integrated health system models and private equity-backed ventures. Recognizing Nonclinical Competencies in Clinical PracticeRegardless

Section snippets MethodsThe VIVA (Viborg Vascular) trial is a population-based, randomized controlled trial of men age 65 to 74 years, who were randomized 1:1 to vascular screening or to no screening. Allocation was based on computer-generated random numbers and stratified into 19 municipalities. Only the control group was masked. In VIVA, AAA was defined as an aortic diameter ≥30 mm measured by 2-dimensional

Section snippets Funding Support and Author DisclosuresDr Butala has received grants from the American Heart Association and the Boettcher Foundation; has received consulting fees from Shockwave Medical, Boston Scientific, Catch Bio, and HiLabs; has an ownership interest in Catch Bio and HiLabs; and has received food/beverages from Medtronic and Edwards. Dr Krishnaswamy has reported that he has no

No Abstract

No Abstract

Section snippets Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program 1979Milton Packer, João Pedro Ferreira, Javed Butler, Gerasimos Filippatos, James L. Januzzi, Jr, Sandra González Maldonado, Marina Panova-Noeva, Stuart J. Pocock, Jürgen H. Prochaska, Maral Saadati, Naveed Sattar, Mikhail Sumin

BackgroundCurrently available antiproprotein convertase subtilisin/kexin type 9 monoclonal antibodies can effectively decrease low-density lipoprotein cholesterol (LDL-C) levels, but require frequent dosing. Recaticimab is a novel humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9. In a phase 1b/2 trial, recaticimab as add-on to stable statins showed robust LDL-C reduction

Randomized clinical trials are the gold standard for establishing the efficacy and safety of cardiovascular therapies. However, current pivotal trials are expensive, lengthy, and insufficiently diverse. Emerging artificial intelligence (AI) technologies can potentially automate and streamline clinical trial operations. This review describes opportunities to integrate AI throughout a trial’s life cycle

The delayed and modest uptake of evidence-based treatments following cardiovascular clinical trials highlights the need for greater attention to implementation early in the development and testing of treatments. However, implementation science is not well understood and is often an afterthought following phase 3 trials. In this review, we describe the goals, frameworks, and methods of implementation

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract